These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 36461127)

  • 1. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
    Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
    Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
    Kwon M; Ku BM; Olsen S; Park S; Lefterova M; Odegaard J; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Med; 2022 Aug; 11(15):2944-2956. PubMed ID: 35437925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
    Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
    EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
    Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
    Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
    Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
    Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
    Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
    Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
    Bordi P; Tiseo M; Rofi E; Petrini I; Restante G; Danesi R; Del Re M
    Clin Lung Cancer; 2017 Nov; 18(6):692-697. PubMed ID: 28601386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma.
    Patel KB; Padhya TA; Huang J; Hernandez-Prera JC; Li T; Chung CH; Wang L; Wang X
    Mol Carcinog; 2023 Apr; 62(4):493-502. PubMed ID: 36636912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
    Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
    Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients.
    Bach S; Wever BMM; van de Wiel MA; Veltman JD; Hashemi SMS; Kazemier G; Bahce I; Steenbergen RDM
    Epigenetics; 2022 Oct; 17(10):1057-1069. PubMed ID: 34605346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
    Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
    Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
    Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
    Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
    Kim S; Kim TM; Kim DW; Go H; Keam B; Lee SH; Ku JL; Chung DH; Heo DS
    J Thorac Oncol; 2013 Apr; 8(4):415-22. PubMed ID: 23344087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.
    Zheng MM; Li YS; Jiang BY; Tu HY; Tang WF; Yang JJ; Zhang XC; Ye JY; Yan HH; Su J; Zhou Q; Zhong WZ; Yang XN; Guo WB; Chuai S; Zhang Z; Chen HJ; Wang Z; Liu C; Wu YL
    J Thorac Oncol; 2019 May; 14(5):924-932. PubMed ID: 30659989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation biomarkers discovered
    Vrba L; Oshiro MM; Kim SS; Garland LL; Placencia C; Mahadevan D; Nelson MA; Futscher BW
    Epigenetics; 2020 Apr; 15(4):419-430. PubMed ID: 31775567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression.
    Sestokaite A; Gedvilaite V; Cicenas S; Sabaliauskaite R; Jarmalaite S
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.